[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-363976-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-363976-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","myc-contributes-to-targeted-therapy-resistance-in-lung-cancers-driven-by-met-exon-14-skipping-alteration","MYC contributes to targeted therapy resistance in lung cancers driven by MET exon 14-skipping alteration","","MET exon 14 skipping (METΔex14) is an oncogenic driver in a subset of lung cancers and can be treated with MET tyrosine kinase inhibitors (TKIs), but resistance limits durability. A preclinical dose-escalation strategy generated MET-TKI-refractory isogenic cells and profiled resistance-associated changes. Targeted sequencing identified acquired SPOP and MGA mutations, which antagonize MYC activity. MYC upregulation mediated resistance, whereas MYC depletion mimicked TKI cytotoxicity. Clinical METΔex14 cases also showed MYC-pathway alterations as resistance mechanisms, supporting combined MYC and MET targeting.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/myc-contributes-to-targeted-therapy-resistance-in-lung-cancers-driven-by-met-exon-14-skipping-alteration/363976/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/myc-contributes-to-targeted-therapy-resistance-in-lung-cancers-driven-by-met-exon-14-skipping-alteration/363976.png","ImageObject",300,407,{"name":42,"@type":43},"PakDamar76","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-17","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is METΔex14 and why is it important in lung cancer?","Question",{"text":63,"@type":64},"MET exon 14 skipping (METΔex14) is a molecular alteration that drives lung cancer and can be targeted with MET tyrosine kinase inhibitors (TKIs).","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was MET-TKI resistance studied in the preclinical model?",{"text":68,"@type":64},"The study used a dose-escalation approach on METΔex14-dependent cancer cells to generate MET-TKI-refractory isogenic counterparts, then profiled and functionally tested clinically relevant changes.",{"name":70,"@type":61,"acceptedAnswer":71},"Which genetic alterations were linked to resistance and how do they affect MYC?",{"text":72,"@type":64},"Targeted sequencing of resistant clones identified acquired mutations in SPOP and MGA, antagonists of MYC activity. These mutations increased MYC levels and showed transcriptomic signatures consistent with MYC activation.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},363976,1790172206,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962090893057,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","npj | precision oncology Article  \n\n| Published in partnership with The Hormel Institute, University of Minnesota |  | |\n| --- | --- | --- |\n| [https://doi.org/10.1038/s41698-026-01410-4](https://doi.org/10.1038/s41698-026-01410-4) |  |  |\n| MYC contributes to targeted therapy resistance in lung cancers driven by MET exon 14-skipping alteration\u003Cbr> Check for updates |  |  |\n| Daniel Lu1,2, Sarah Okun3,4, Tom Zhang5,6, Andrea Gazzo1,2, Amy Kang2, Amy Nagelberg3,4,\u003Cbr>Justine L. M. Chow3, Haijie Liang1,2, Anmol Kustagi5,7, Christopher A. Febres-Aldana8, Marc Ladanyi1,2, Romel Somwar1,2 & William W. Lockwood3,9  |  |  |\n| MET-exon-14 skipping mutations (METΔex14) are oncogenic drivers in ~3–5% of lung cancer, which can be targeted with MET tyrosine kinase inhibitors (TKIs). The emergence of resistance limits longterm responses and is commonly mediated by secondary genomic alterations. We devised apreclinical strategy to study MET-TKI resistance using a dose-escalation approach on METΔex14-dependent cancer cells to generate MET-TKI-refractory isogenic counterparts. These cell lines were proﬁled for clinically relevant changes that we functionally evaluated for MET-TKI resistance. Targeted sequencing of resistant clones identiﬁed acquired mutations in SPOP and MGA, both antagonists of MYC activity. SPOP-and MGA-mutant clones exhibited higher MYC levels and transcriptomic signatures of MYC activation. Expression of MYC rescued tumor growth in the presence ofTKI, while MYC depletion mimicked the cytotoxic effect ofTKI treatment, indicating that MYC activity is coupled to MET signaling and MYC is required to mediate drug resistance. Analysis of clinical METΔex14-positive lung cancers revealed several cases where acquired MYC pathway alterations mediated resistance to MET-TKIs. These ﬁndings collectively converge on MYC as key in the progression of MET TKI-resistant cancers, and our in vitro data support the strategy of co-targeting MYC and MET to yield more prolonged responses in patients with METΔex14-positive lung cancer. |  |  |\n| The METgene encodes a cell surface receptor tyrosine kinase(RTK), which is involved in lung cancer (LC) initiation and progression1. Under physiologic conditions, this receptor regulates cellular homeostasis by integrating growth, motility, and survival cues from the environment, typically in the context ofwound healing and development2,3. Aberrantly upregulated MET promotes drug resistance and metastatic dissemination of the primary tumor3–10. Oncogenic activation of MET in LC is observed in the setting of MET mutations, ampliﬁcation, fusions, and/or overexpression. Splice site mutations resulting in MET exon 14 skipping isoforms (METΔex14) constitute a distinct molecular subclass11. Loss of exon 14, which encodes the receptor juxtamembrane regulatory domain, prevents MET ubiquitination and increases the stability of MET-RTK in an active state, leading to MET | hyperactivation, cellular transformation, and tumorigenesis12–14. Importantly, patients bearing METΔex14-positive tumors exhibit improved outcomes when treated with MET-selective inhibitors15–19.\u003Cbr>With the recent approval of anti-MET inhibitors for ﬁrst-line therapy in METΔex14-positive LUAD patients, eventual drug resistance is now often observed, resulting in disease progression for a signiﬁcant fraction of patients. Clinical and pre-clinical studies evaluating tyrosine kinase inhibitors (TKIs) targeting RTKs – EGFR, ALK, RET, and ROS1—have shown that lung tumors achieve resistance through a multitude ofmechanisms20–22. These range from on-target mutations affecting drug binding, to off-target mutations rewiring parallel or downstream signaling pathways, to lineage transformation asa driver ofadaptive growth23,24. Precision oncology allows |  |\n\n1Human Oncology & Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 2Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY","cbCailvVtLlbh4PY","https://ap.wps.com/l/cbCailvVtLlbh4PY","pdf",3588060,14,"English","# Background\n# Preclinical strategy to model MET-TKI resistance\n## Generation of resistant isogenic cell lines\n## Profiling and functional evaluation of resistance changes\n# Mechanism of resistance involving MYC\n## Acquired mutations in SPOP and MGA\n## MYC activation and coupling to MET signaling\n# Clinical relevance in METΔex14-positive lung cancers\n# Therapeutic implication: co-targeting MYC and MET","[{\"question\":\"What is METΔex14 and why is it important in lung cancer?\",\"answer\":\"MET exon 14 skipping (METΔex14) is a molecular alteration that drives lung cancer and can be targeted with MET tyrosine kinase inhibitors (TKIs).\"},{\"question\":\"How was MET-TKI resistance studied in the preclinical model?\",\"answer\":\"The study used a dose-escalation approach on METΔex14-dependent cancer cells to generate MET-TKI-refractory isogenic counterparts, then profiled and functionally tested clinically relevant changes.\"},{\"question\":\"Which genetic alterations were linked to resistance and how do they affect MYC?\",\"answer\":\"Targeted sequencing of resistant clones identified acquired mutations in SPOP and MGA, antagonists of MYC activity. These mutations increased MYC levels and showed transcriptomic signatures consistent with MYC activation.\"}]","MYC contributes to targeted therapy resistance in lung cancers driven by MET exon 14-skipping alteration | PDF",1790154725,35,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3aa919fe7fc98d403dbe121b921ca1dd.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ece140c0fa8adf348b6d7c315eff8b32.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/41d32dc817854afa0611ace0187d1e07.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1c81217e0e2e480bf49679088f5cfce0.webp",980,1301]